热门资讯> 正文

Arcus Biosciences售价2.5亿美元

2025-10-31 12:40

Arcus Biosciences(RCUS) 0

Clinical-stage, global biopharmaceutical company Arcus Biosciences (RCUS) priced an underwritten public offering of 13.7M shares at $18.25 per share.
Gross proceeds are expected to be $250M.
The underwriters have a 30-day option to purchase up to 2.06M additional shares.
The offering is expected to close on November 3, 2025.
The stock price slumped 6% on Friday during pre-market hours of trading.

More on Arcus Biosciences

Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call - Slideshow
Arcus Biosciences rises on results from domvanalimab cancer study
Arcus Biosciences Q2 2025 Earnings Preview

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。